Results 131 to 140 of about 113,306 (267)

Discovery of new Schiff bases of the disalicylic acid scaffold as DNA gyrase and topoisomerase IV inhibitors endowed with antibacterial properties

open access: yesFrontiers in Chemistry
DNA gyrase and topoisomerase IV show great potential as targets for antibacterial medicines. In recent decades, various categories of small molecule inhibitors have been identified; however, none have been effective in the market.
Lamya H. Al-Wahaibi   +8 more
doaj   +1 more source

Trastuzumab Deruxtecan for HER2‐Low Metastatic Breast Cancer: Practical Considerations for Medical Oncologists and Pathologists in Australia

open access: yesAsia-Pacific Journal of Clinical Oncology, Volume 22, Issue 3, Page 381-391, June 2026.
ABSTRACT Trastuzumab deruxtecan (T‐DXd) is a third‐generation, HER2‐targeting antibody‐drug conjugate that has been shown to significantly prolong overall survival, compared with standard chemotherapy, when used to treat patients who have “HER2‐low” (HER2 immunohistochemistry [IHC] score 1+; or HER2 IHC 2+ plus in situ hybridization‐negative ...
Andrew Redfern   +8 more
wiley   +1 more source

Production Performance and Ameliorative Effects of Switchgrass on Severely Saline‐Alkali Land in Coastal Areas of China

open access: yesGCB Bioenergy, Volume 18, Issue 6, June 2026.
Switchgrass cultivation sustained biomass production while rapidly improving soil structure and reducing salinity in coastal saline‐alkali soils. These changes reshaped microbial communities through environmental filtering, establishing plant‐soil‐microbe feedbacks that support both bioenergy production and ecological restoration.
Aoxiang Chang   +17 more
wiley   +1 more source

Common Hematologic Emergencies—Acute Promyelocytic Leukemia and Microangiopathic Hemolytic Anemias—A Pivotal Role of Clinical Laboratory

open access: yesInternational Journal of Laboratory Hematology, Volume 48, Issue 3, Page 521-530, June 2026.
ABSTRACT Hematologic emergencies are urgent health conditions which result in significant mortality and morbidity unless timely therapeutic measures are taken. Therapeutic success depends on their timely and accurate recognition by hematology laboratory services.
Ganna Shestakova   +2 more
wiley   +1 more source

Clonal hematopoiesis in patients with cancer and cancer survivors: From clonal burden to cardiovascular diseases

open access: yesCancer, Volume 132, Issue 10, 15 May 2026.
ABSTRACT Over the past decade, clonal hematopoiesis (CH) has gained substantial attention as a prevalent, age‐associated phenomenon with major implications for hematologic malignancy, cardiovascular disease, and mortality. CH arises from the clonal expansion of hematopoietic stem cells and progenitor cells harboring somatic mutations, most commonly in ...
Christian H. Nenninger   +7 more
wiley   +1 more source

Detection of Diagnostic Antibodies in Immune‐Mediated Diseases: A Focus on Antigens and Technologies

open access: yesChemBioChem, Volume 27, Issue 9, 14 May 2026.
This review explores autoantibody detection in immune‐mediated diseases, highlighting autoantigens including post‐translational modifications. We compared enzyme‐linked immunosorbent assay and indirect immunofluorescence with automated chemiluminescence platforms.
Silvia Bracci   +5 more
wiley   +1 more source

MicroRNA‐Mediated Regulation of Brain Aging Hallmarks: Implications for Neurodegeneration and Neural Recovery

open access: yesBrain and Behavior, Volume 16, Issue 5, May 2026.
Hallmarks of brain aging regulated by microRNAs (miRNAs). This graphical abstract illustrates the central role of miRNAs in coordinating key biological processes associated with brain aging. miRNAs regulate multiple interconnected hallmarks, including genomic instability, telomere attrition, epigenetic alterations, loss of proteostasis and impaired ...
Mustafa T. Ardah   +7 more
wiley   +1 more source

MGL‐Based Drug Conjugate: A Novel Glycan‐Targeting Strategy for Potential Precision Cancer Therapy

open access: yesChemistryEurope, Volume 4, Issue 5, May 2026.
An engineered macrophage galactose‐type lectin (MGL)‐based conjugate (mMGL‐vcMMAE), incorporating an exposed cysteine for site‐specific drug linkage, preserves stability, binding profile, and affinity of the native MGL carbohydrate recognition domain. It also selectively targets Tn/STn‐expressing cancer cells and shows recognition of colorectal cancer ...
Carlos D. L. Lima   +15 more
wiley   +1 more source

Targeting DNA topoisomerases: past & future

open access: yesCancer Drug Resistance, 2021
Gmeiner, William H.   +1 more
openaire   +3 more sources

Targeting the nuclear export receptor exportin‐1 in acute myeloid leukaemia: From biology to clinical translation

open access: yesClinical and Translational Medicine, Volume 16, Issue 5, May 2026.
• XPO1 hyperactivation promotes leukaemogenesis by altering nucleocytoplasmic transport and transcriptional control in acute myeloid leukaemia (AML). • Selinexor and eltanexor show preferential activity in NPM1‐mutated, DEK::NUP214‐positive and SF3B1‐mutated myeloid neoplasms.
Yifan Liu   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy